Business Context and Reporting Period
This Form 8-K filing by Arcus Biosciences, Inc. reports corporate governance changes effective as of December 31, 2018, and January 2019. The company is a Delaware corporation focused on biopharmaceuticals.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and associated compensation arrangements.
Material Changes
- Resignation of CFO: Jennifer Jarrett, Chief Financial and Operating Officer, resigned effective January 11, 2019.
- Board Expansion: The Board of Directors increased in size from six to seven members.
- Appointment of New CFO: Steven Chan, previously Vice President of Finance and Principal Accounting Officer, was appointed Principal Financial Officer effective January 12, 2019.
- Board Appointment: Jennifer Jarrett was appointed as a Class III non-employee director effective January 12, 2019.
Compensation and Management Commentary
Ms. Jarrett entered a separation and consulting agreement to provide services until January 11, 2020. Her compensation includes:
- Payment of her 2018 annual target bonus of $200,000.
- Continued vesting of outstanding stock options per original terms.
- As a non-employee director, an annual cash retainer of $35,000.
- Grant of an option to purchase 35,000 shares of common stock, vesting monthly over 36 months.
Mr. Chan brings prior experience leading finance functions at MyoKardia, Inc. (through its 2015 IPO), Solta Medical, Inc., and Moody's Analytics.
Investor Verification Checklist
- Verify the transition timeline for financial reporting responsibilities between Ms. Jarrett and Mr. Chan.
- Confirm the impact of the $200,000 bonus payment on the company's immediate cash position.
- Review the vesting schedule and change-in-control provisions for the new 35,000-share option grant to Ms. Jarrett.
- Assess the stability of the finance team given the simultaneous departure of the CFO and appointment of the successor.